The Daily Start-Up: CMEA Pursues Capital Efficiency In Biotech
Looking to boost its biotech investment returns, CMEA Capital has decided to act like a drug company. Instead of backing biotech start-ups, the San Francisco-based firm will look to acquire early-stage compounds, develop them through mid-stage clinical trials and then sell the best prospects to pharmaceutical companies. The firm views this strategy as a more capital-efficient way to develop drugs. VentureWire has more.
Read more: Wall Street Journal The Daily Start-Up: CMEA Pursues Capital Efficiency In Biotech